Tonix Pharmaceuticals stock halted ahead of FDA approval news
ARLINGTON, VA—Glass Russell Monroe, a director at Evolent Health, Inc. (NYSE:EVH), recently acquired 5,400 shares of Class A Common Stock. The transaction, dated March 6, 2025, involved a purchase at a price of $9.27 per share, totaling approximately $50,058. This insider purchase comes as InvestingPro data shows the stock trading significantly below its 52-week high of $34.84, suggesting management’s confidence in the company’s value proposition.
Following this transaction, Monroe directly owns 14,272 shares. Additionally, there are 6,046 shares held indirectly in a trust, which Monroe and his spouse co-manage. This acquisition adds to his existing stock holdings, which include restricted stock units from previous awards. According to InvestingPro analysis, management has been actively buying back shares, aligning with this insider purchase pattern.
Evolent Health, headquartered in Arlington, Virginia, continues to be a focal point for investors monitoring insider activities. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with analysts setting price targets ranging from $12 to $20 per share. Discover more insights and 8 additional ProTips about EVH with an InvestingPro subscription.
In other recent news, Evolent Health reported fourth-quarter results that did not meet analyst expectations, with an adjusted earnings per share of -$0.02, missing the consensus estimate of $0.07. Revenue for the quarter was $646.5 million, slightly below projections of $652.2 million, although it marked a 16.3% increase year-over-year. For the full year 2024, Evolent’s revenue reached $2.55 billion, showing a growth of 30.1% over the previous year. However, the company’s 2025 revenue forecast of $2.06 billion to $2.11 billion fell short of the anticipated $2.42 billion, causing concern among investors.
Piper Sandler adjusted its price target for Evolent Health to $16 from $17, maintaining an Overweight rating, following the company’s earnings report. Despite the reduced target, Piper Sandler remains optimistic about Evolent’s value proposition, highlighting strong customer retention and bookings. In contrast, Citizens JMP increased its price target for Evolent Health to $13 from $12, reaffirming a Market Outperform rating. Analyst Constantine Davides expressed confidence in Evolent’s management and its ability to handle external challenges, suggesting a more predictable profit generation moving forward.
Evolent Health’s recent earnings report and subsequent analyst updates reflect the company’s current financial health and future prospects. The firm has managed to retain 100% of its top customers, who account for over 90% of its revenue, and has signed new revenue agreements. These developments, along with the analysts’ perspectives, provide a nuanced view of Evolent Health’s position in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.